Shuttle Pharma appoints Christopher Cooper interim CEO; founder Dritschilio CSO & Chairman

Shuttle Pharmaceuticals Holdings, Inc.

Christopher Cooper appointed interim CEO effective March 30, 2025.
Founder Dr. Anatoly Dritschilio becomes Chief Scientific Officer, remains Chairman of the Board.
Amended employment agreement: 3-year term, $274,000/year base salary, 12-month severance.
Dritschilio tasked with completing Phase 2 Ropidoxuridine glioblastoma trial by 2026, initiating Phase 3 by 2028.
Restructuring aims to add expertise in business and capital markets activities.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Christopher Cooper

interim Chief Executive Officer

SHPH · Shuttle Pharmaceuticals Holdings, Inc.

Effective: 2025-03-30
Filed: March 31, 2025, 7:59 PM ET

Effective March 30, 2025, the Company’s Board of Directors approved the appointment of Christopher Cooper to the position of interim Chief Executive Officer

Role change

Anatoly Dritschilo

Chief Scientific Officer

SHPH · Shuttle Pharmaceuticals Holdings, Inc.

Effective: 2025-03-30
Successor: Christopher Cooper
Filed: March 31, 2025, 7:59 PM ET

Anatoly Dritschilo, M.D., to the position of Chief Scientific Officer. Dr. Dritschilo will also continue to hold the position of Chairman of the Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Cooper was appointed as interim Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..

Action: appointed
Role: interim Chief Executive Officer

Exact text from the filing

Effective March 30, 2025, the Company’s Board of Directors approved the appointment of Christopher Cooper to the position of interim Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Anatoly Dritschilo was appointed as Chief Scientific Officer at Shuttle Pharmaceuticals Holdings, Inc..

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

Anatoly Dritschilo, M.D., to the position of Chief Scientific Officer. Dr. Dritschilo will also continue to hold the position of Chairman of the Board of Directors.

View on SEC.gov

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-001880

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.